Home › Neuroblastoma › Massachusetts
Pag-aaral pangklinika para sa Neuroblastoma sa Massachusetts
13 pag-aaral para sa Neuroblastoma ang naghahanap ng mga kalahok sa mga site sa Massachusetts.
Mga Lungsod sa Massachusetts
Opisyal na teksto ng pag-aaral (English)
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- Dana-Farber Cancer Institute, Boston
Nagre-recruit
Hanggang edad 17 · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT06831552Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 3
Hanggang edad 30 · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT06172296Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 1013), Boston
Nagre-recruitPhase 1/2
6 Months – 25 Years · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT06395103PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Okt 6, 2026 · NCT06721689MCT for the Harvard/UCSF ROBIN Center
- Brigham and Women's Hospital, Boston
Nagre-recruit
Lahat ng edad · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06000787B7-H3.CD28Z.CART in Solid Tumors
- Dana Farber Cancer Institite, Boston
Nagre-recruitPhase 1
9 Months – 30 Years · Lahat ng kasarian · Na-update Set 3, 2026 · NCT07358260Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 3
365 Days – 30 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04851119SPEARHEAD-3 Pediatric Study
- Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
Edad 2 hanggang 21 · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT05642455NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Boston Children's Hospital, Dana-Farber Cancer Institute., Boston
Nagre-recruitPhase 2
Edad 1 hanggang 31 · Lahat ng kasarian · Na-update Hul 20, 2026 · NCT06450041Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Hul 14, 2026 · NCT07027748Neuroblastoma Biology Study
- Children's Hospital Boston, Boston
Nagre-recruitObservasyonal na pag-aaral
31 Days – 99 Years · Lahat ng kasarian · Na-update Mar 23, 2026 · NCT01587300Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
12 Months – 29 Years · Lahat ng kasarian · Na-update Dis 26, 2025 · NCT06803875Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.